达格列净辅助治疗1型糖尿病52周研究:DEPICT-1
DEPICT-1为随机双盲安慰剂对照3期研究,833例血糖控制不佳的1型糖尿病患者接受达格列净5mg、10mg或安慰剂治疗52周。达格列净显著降低HbA1c和体重,但增加糖尿病酮症酸中毒(DKA)风险。
要点
- 达格列净5mg和10mg治疗52周显著降低HbA1c和体重。
- 达格列净组DKA发生率高于安慰剂组。
- 低血糖事件在各组间相当,严重不良事件发生率相近。
核心结论
- 达格列净辅助胰岛素治疗1型糖尿病可改善血糖控制和减重,但增加DKA风险。
研究设计与样本
- 随机(1:1:1)、双盲、安慰剂对照3期研究,纳入833例HbA1c 7.5-10.5%的1型糖尿病患者,比较达格列净5mg、10mg与安慰剂,52周(24周短期+28周扩展)。
主要发现
- 52周时,达格列净5mg和10mg组HbA1c较安慰剂组分别降低0.33%(95%CI -0.49至-0.17)和0.36%(95%CI -0.53至-0.20)。
- 52周时,达格列净5mg和10mg组体重较安慰剂组分别降低2.95%(95%CI -3.83至-2.06)和4.54%(95%CI -5.40至-3.66)。
- 严重不良事件发生率在达格列净5mg、10mg和安慰剂组分别为13.4%、13.5%和11.5%。
- 低血糖事件在各组间相当,但DKA(判定为明确DKA)发生率在达格列净5mg、10mg和安慰剂组分别为4.0%、3.4%和1.9%。
临床怎么用
- 对于血糖控制不佳的1型糖尿病患者,可考虑在胰岛素基础上加用达格列净以改善血糖和减轻体重,但需警惕DKA风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluated the long-term safety and efficacy of dapagliflozin as an adjunct to adjustable insulin in patients with type 1 diabetes and inadequate glycemic control. RESEARCH DESIGN AND METHODS: DEPICT-1 (Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes) was a randomized (1:1:1), double-blind, placebo-controlled phase 3 study of dapagliflozin 5 mg and 10 mg in patients with type 1 diabetes (HbA1c 7.5-10.5% [58-91 mmol/mol]) (NCT02268214). The results of the 52-week study, consisting of the 24-week short-term and 28-week extension period, are reported here. RESULTS: Of the 833 patients randomized into the study, 708 (85%) completed the 52-week study. Over 52 weeks, dapagliflozin 5 mg and 10 mg led to clinically significant reductions in HbA1c (difference vs. placebo [95% CI] -0.33% [-0.49, -0.17] [-3.6 mmol/mol (-5.4, -1.9)] and -0.36% [-0.53, -0.20] [-3.9 mmol/mol (-5.8, -2.2)], respectively) and body weight (difference vs. placebo [95% CI] -2.95% [-3.83, -2.06] and -4.54% [-5.40, -3.66], respectively). Serious adverse events were reported in 13.4%, 13.5%, and 11.5% of patients in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively. Although hypoglycemia events were comparable across treatment groups, more patients in the dapagliflozin groups had events adjudicated as definite diabetic ketoacidosis (DKA; 4.0%, 3.4%, and 1.9% in dapagliflozin 5 mg, 10 mg, and placebo groups, respectively). CONCLUSIONS: Over 52 weeks, dapagliflozin led to improvements in glycemic control and weight loss in patients with type 1 diabetes, while increasing the risk of DKA.
引用
- Dandona P, Mathieu C, Phillip M, et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care. 2018. PMID: 30352894. doi:10.2337/dc18-1087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。